Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Poliomyelitis

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment.

Journal of neurology·2025

Same author

Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRI: a prospective cohort study.

Journal of neurology·2025

Same author

Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.

Journal of neurology·2024

Same author

Acute amnestic syndrome in fornix lesions: a systematic review of reported cases with a focus on differential diagnosis.

Frontiers in neurology·2024

Same author

Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis.

Multiple sclerosis and related disorders·2022

Same author

Brain plasticity after rehabilitation in a severe case of artery of Percheron stroke assessed with multimodal MR imaging.

Neurocase·2022

Search research articles

Related Experiment Videos

NMO-IgG-negative relapsing myelitis.

S Ravaglia¹, S Bastianello, D Franciotta

¹Institute of Neurology C Mondino, University of Pavia, Pavia, Italy. sabrina.ravaglia@mondino.it

|December 24, 2008

Summary

This summary is machine-generated.

Relapsing idiopathic transverse myelitis (I-TM) occurs in 31% of cases and is a distinct entity. This form of I-TM shares features with post-infectious transverse myelitis (P-TM) and is unpredictable.

Related Experiment Videos

Area of Science:

Neurology
Immunology
Infectious Diseases

Background:

Idiopathic transverse myelitis (I-TM) is typically monophasic.
Relapsing forms are often misdiagnosed as neuromyelitis optica (NMO) or multiple sclerosis (MS).
Distinguishing I-TM from other myelitis forms is crucial for accurate diagnosis and management.

Purpose of the Study:

To determine the frequency of recurrent I-TM.
To clarify the nosology of relapsing I-TM by comparing it with NMO and post-infectious TM (P-TM).

Main Methods:

Prospective cohort study of patients with I-TM and P-TM over 8 years.
Follow-up included clinical assessments, MRI, evoked potentials, and serological tests.
Relapses were defined by clinical and imaging criteria.

Main Results:

31% of I-TM patients experienced relapses, predominantly males over 50 with severe onset disability.
Relapsing I-TM did not show NMO-immunoglobulin G and was not predicted by longitudinally extensive myelitis.
I-TM and P-TM shared clinical, CSF, and MRI features, including a similar relapse rate (31%).

Conclusions:

Relapsing I-TM is a distinct disease entity, unrelated to NMO or MS.
This form shares significant features with P-TM.
Relapse likelihood in I-TM is unpredictable based on current clinical, CSF, and MRI findings.